Phaseline

Companies › Biomea Fusion

Biomea Fusion: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
icovamenib 100 mg
Menin inhibitor
MEN1Phase 2Type 2 DiabetesMar 2027
BMF-650–Phase 1Obesity–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07223216BMF-650Phase 1ObesityMetabolic and endocrineAug 2026
NCT07502495icovamenib 100 mgPhase 2Type 2 DiabetesMetabolic and endocrineMar 2027
NCT07502508icovamenib 100 mgPhase 2Type 2 DiabetesMetabolic and endocrineJun 2027

From the company's SEC filings

Cash of $35m on 2026-06-30; operating cash outflow about $44m a year; runway about 10 months at that burn, to Apr 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MEN1 (1)

Companies with the same targets

Kura Oncology Syndax Pharmaceuticals Johnson & Johnson (Janssen) Sumitomo Pharma America

Companies built like this

Yarrow Bioscience JCR Pharmaceuticals Amorphical ERX Pharmaceuticals Hyundai Pharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.